Clinical Trials Logo
  1. Home
  2. Intracerebral Haemorrhage
  3. NCT05369351

Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage

Intracerebral Haemorrhage Clinical Trial

Official title:
Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage

Clinical Trial Summary

Intracerebral hemorrhage (ICH) accounts for 10-15% of all strokes without effective pharmacological treatment. Inflammation following ICH contributes to barrier disruption and peri-hematoma edema, leading to deterioration of neurological function. Preclinical evidence suggests that bone marrow hematopoietic stem and progenitor cells (HSPCs) are swiftly activated after ICH. Thereafter, these HSPCs produce an increased output of anti-inflammatory monocytes as an endogenous protective mechanism. Stimulation of β3 adrenergic receptor using selective agonists promotes the production of anti-inflammatory monocytes in bone marrow, and thereby reduces neuroinflammation, brain edema and neurological deficits. This study is to assess the safety and efficacy of a β3 adrenergic receptor agonist Mirabegron as a potential treatment option in ICH patients.

Clinical Trial Description

This study is to evaluate the efficacy and safety of mirabegron in patients with intracerebral hemorrhage based on standard therapy ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05369351
Study type Interventional
Source Tianjin Medical University General Hospital
Contact Handong Li
Phone +8615022439149
Email handongli90@foxmail.com
Status Recruiting
Phase Phase 2
Start date January 17, 2024
Completion date November 10, 2026
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06429332 - International Care Bundle Evaluation in Cerebral Hemorrhage Research Phase 4
Completed NCT01563445 - Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII for Preventing Early Hematoma Growth in Acute Intracerebral Haemorrhage Phase 2
Not yet recruiting NCT06410274 - Ischaemic Lesions in Acute Intracerebral Haemorrhage
Completed NCT00127283 - Recombinant Factor VIIa in Acute Intracerebral Haemorrhage Phase 3
Completed NCT03737344 - BLOC-ICH: Interleukin-1 Receptor Antagonist in Intracerebral Haemorrhage Phase 2
Completed NCT02162017 - Head Position in Stroke Trial (HeadPoST) N/A
Completed NCT03385928 - STOP-MSU: Stopping Haemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units Phase 2
Recruiting NCT06067750 - Comparison of Narcotrend and Cerebral Function Analysing Monitor in Intensive Care to Monitor Seizures and Deep Sedation
Active, not recruiting NCT01947361 - Heart Rate and Initial Presentation of Cardiovascular Diseases (Caliber) N/A
Active, not recruiting NCT01937065 - Social Deprivation and Initial Presentation of 12 Cardiovascular Diseases: a CALIBER Study N/A
Completed NCT00266006 - Factor VIIa in Acute Intracerebral Haemorrhage Phase 2
Recruiting NCT05681988 - Early Minimally Invasive Image Guided Endoscopic Evacuation of Intracerebral Haemorrhage (EMINENT-ICH) N/A
Completed NCT02880878 - ENRICH: Early MiNimally-invasive Removal of IntraCerebral Hemorrhage (ICH) N/A
Completed NCT02176174 - Ethnicity and Onset of Cardiovascular Disease: A CALIBER Study N/A
Completed NCT01702636 - STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial Phase 2
Active, not recruiting NCT01320423 - Surgical Trial in Lobar Intracerebral Haemorrhage N/A
Completed NCT00426803 - Recombinant Factor VIIa in Acute Intracerebral Haemorrhage Phase 2
Completed NCT01566786 - Safety and Preliminary Efficacy of Activated Recombinant Human Factor VII in Acute Intracerebral Haemorrhage Phase 2
Recruiting NCT03044184 - Tranexamic Acid for Spontaneous Acute Cerebral Hemorrhage Trial Phase 3